1) On what date did the Board decide to abandon the previously communicated plan of analysing the Observational Dialysis study and then entering into discussions with the FDA on the design of an Intervention study? 2) What expert advice informed this decision and from whom was it received? 3) Now that the Observational data is available and has been discussed with the PIs why has it not been released to Shareholders? 4) Are the Board aware of the meta analysis of all previous intervention studies of Imedance technology in Dialsis patients ( Yang et al 2023) and the finding of a relative risk of MORTALITY of 0.71 or a 30% reduction pooling data from 14 studies and 2631 patients? In light of this how do the Board justify abandoning their previous plan? 5) Why do the Board remain entirely focused on questions of reimbursement in USA and concerns about the perceived Duopoly of private dialysis companies in the USA? Are they not able of developing a viable business plan to pursue the potential of the technology in Renal and Cardiac patients outside the USA?
IPD Price at posting:
16.5¢ Sentiment: Hold Disclosure: Held
